期刊
CANCER LETTERS
卷 404, 期 -, 页码 62-69出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.06.030
关键词
Melanoma; Liquid biopsy; ctDNA; Circulating tumour DNA; Cell-free DNA
类别
资金
- Western Australia Cancer Council [1100249]
- Cancer Research Trust
Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been shown to have clinical value as an alternative tumour source for the detection clinically targetable mutations for the assessment of response to therapy, This review provides a critical summary of the evidence that gives credence to the utility of ctDNA as a biomarker for monitoring of disease status in advanced melanoma and the steps required for its implementation into clinical settings. (C) 2017 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据